Clinical study of BXCL502 as a potential monotherapy and in combination with BXCL501 for chronic treatment of agitation in patients with dementia
Latest Information Update: 25 Nov 2021
At a glance
- Drugs BXCL 502 (Primary) ; Dexmedetomidine (Primary)
- Indications Agitation
- Focus Adverse reactions
- 25 Nov 2021 New trial record
- 10 Nov 2021 According to a BioXcel Therapeutics media release, formulation and clinical development planning is underway.